CN109180499B - 甲磺酸雷沙吉兰及其中间体的制备方法 - Google Patents
甲磺酸雷沙吉兰及其中间体的制备方法 Download PDFInfo
- Publication number
- CN109180499B CN109180499B CN201810856618.6A CN201810856618A CN109180499B CN 109180499 B CN109180499 B CN 109180499B CN 201810856618 A CN201810856618 A CN 201810856618A CN 109180499 B CN109180499 B CN 109180499B
- Authority
- CN
- China
- Prior art keywords
- gas
- rasagiline
- preparation
- reaction
- mesylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 69
- JDBJJCWRXSVHOQ-UTONKHPSSA-N methanesulfonic acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2[C@H](NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UTONKHPSSA-N 0.000 title claims abstract description 40
- 229960001956 rasagiline mesylate Drugs 0.000 title claims abstract description 40
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims abstract description 96
- 229960000245 rasagiline Drugs 0.000 claims abstract description 94
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000003960 organic solvent Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 18
- 239000003054 catalyst Substances 0.000 claims abstract description 17
- 238000006722 reduction reaction Methods 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract description 14
- 239000007789 gas Substances 0.000 claims description 103
- 239000002904 solvent Substances 0.000 claims description 48
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- 238000005406 washing Methods 0.000 claims description 28
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 claims description 25
- 238000001914 filtration Methods 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 238000010791 quenching Methods 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 238000001291 vacuum drying Methods 0.000 claims description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 230000000171 quenching effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000006482 condensation reaction Methods 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 150000008282 halocarbons Chemical group 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001681 protective effect Effects 0.000 claims description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 6
- 150000004945 aromatic hydrocarbons Chemical group 0.000 claims description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 4
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 claims description 4
- OKHRRIGNGQFVEE-UHFFFAOYSA-N methyl(diphenyl)silicon Chemical compound C=1C=CC=CC=1[Si](C)C1=CC=CC=C1 OKHRRIGNGQFVEE-UHFFFAOYSA-N 0.000 claims description 4
- AKQNYQDSIDKVJZ-UHFFFAOYSA-N triphenylsilane Chemical compound C1=CC=CC=C1[SiH](C=1C=CC=CC=1)C1=CC=CC=C1 AKQNYQDSIDKVJZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 9
- 238000009776 industrial production Methods 0.000 abstract description 5
- 238000007086 side reaction Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000007281 aminoalkylation reaction Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 108
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 106
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 53
- 235000017557 sodium bicarbonate Nutrition 0.000 description 53
- 239000007864 aqueous solution Substances 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 32
- 238000003756 stirring Methods 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000008280 chlorinated hydrocarbons Chemical group 0.000 description 6
- 239000002274 desiccant Substances 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- -1 seguinine Substances 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- OWAHJGWVERXJMI-UHFFFAOYSA-N prop-2-ynyl methanesulfonate Chemical compound CS(=O)(=O)OCC#C OWAHJGWVERXJMI-UHFFFAOYSA-N 0.000 description 2
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940031774 azilect Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/50—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810856618.6A CN109180499B (zh) | 2018-07-31 | 2018-07-31 | 甲磺酸雷沙吉兰及其中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810856618.6A CN109180499B (zh) | 2018-07-31 | 2018-07-31 | 甲磺酸雷沙吉兰及其中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109180499A CN109180499A (zh) | 2019-01-11 |
CN109180499B true CN109180499B (zh) | 2021-04-30 |
Family
ID=64937495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810856618.6A Active CN109180499B (zh) | 2018-07-31 | 2018-07-31 | 甲磺酸雷沙吉兰及其中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109180499B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003093251A1 (en) * | 2002-05-01 | 2003-11-13 | Merck Sharp & Dohme Limited | Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase |
CN101062897A (zh) * | 2006-04-25 | 2007-10-31 | 重庆医药工业研究院有限责任公司 | 一种制备2,3-二氢-1h-茚-1-胺及其衍生物的改进方法 |
CN101260048A (zh) * | 2008-04-15 | 2008-09-10 | 苏州凯达生物医药技术有限公司 | 雷沙吉兰的制备方法 |
CN102464589A (zh) * | 2010-11-17 | 2012-05-23 | 凯瑞斯德生化(苏州)有限公司 | 雷沙吉兰、其甲磺酸盐及其中间体的制备方法 |
CN102786422A (zh) * | 2011-05-17 | 2012-11-21 | 上海特化医药科技有限公司 | 一种制备甲磺酸雷沙吉兰的方法 |
CN106852143A (zh) * | 2014-07-02 | 2017-06-13 | 埃斯蒂维实验室股份有限公司 | 三环***化合物 |
-
2018
- 2018-07-31 CN CN201810856618.6A patent/CN109180499B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003093251A1 (en) * | 2002-05-01 | 2003-11-13 | Merck Sharp & Dohme Limited | Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase |
CN101062897A (zh) * | 2006-04-25 | 2007-10-31 | 重庆医药工业研究院有限责任公司 | 一种制备2,3-二氢-1h-茚-1-胺及其衍生物的改进方法 |
CN101260048A (zh) * | 2008-04-15 | 2008-09-10 | 苏州凯达生物医药技术有限公司 | 雷沙吉兰的制备方法 |
CN102464589A (zh) * | 2010-11-17 | 2012-05-23 | 凯瑞斯德生化(苏州)有限公司 | 雷沙吉兰、其甲磺酸盐及其中间体的制备方法 |
CN102786422A (zh) * | 2011-05-17 | 2012-11-21 | 上海特化医药科技有限公司 | 一种制备甲磺酸雷沙吉兰的方法 |
CN106852143A (zh) * | 2014-07-02 | 2017-06-13 | 埃斯蒂维实验室股份有限公司 | 三环***化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN109180499A (zh) | 2019-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7645880B2 (en) | Processs for preparing N-alkylnaltrexone halides | |
TW201429924A (zh) | 經精製之胺化合物的製造方法 | |
US20080103334A1 (en) | Process For Synthesis Of Gabapentin | |
CN102395591A (zh) | 一种合成普拉格雷的方法 | |
CN113683651A (zh) | 一种GalNAc中间体的制备方法 | |
CN109180499B (zh) | 甲磺酸雷沙吉兰及其中间体的制备方法 | |
CN112979448B (zh) | 一种高选择性5-溴-2-氯苯甲酸的制备方法 | |
CN107674062B (zh) | 抗丙肝药物中间体、制备方法及应用 | |
EP1347951B1 (en) | A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
CN109485664B (zh) | 一种抗真菌药物他伐硼罗的制备工艺 | |
CN109721603B (zh) | 一种低氧靶向肿瘤细胞dna修复酶mgmt抑制剂及其制备方法与应用 | |
AU2002229575A1 (en) | A process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
CN108084115B (zh) | 盐酸普拉克索及其中间体的制备方法 | |
CN110551052A (zh) | (r)-4-羟基-2-氧代-1-吡咯烷乙酸酯的制备方法 | |
CA2198781C (en) | Preparation of selegiline | |
US20140205666A1 (en) | Iminosugar in crystalline form | |
KR100809159B1 (ko) | 로사탄의 개선된 제조방법 | |
CN111320569B (zh) | 一种哌马色林固态中间体的制备方法 | |
CN108912020B (zh) | 奥当卡替及其中间体的制备方法 | |
CN111018692B (zh) | 以超强碱法制备1,2,3,4-四氢-1-萘甲酸的方法 | |
WO2016101714A1 (zh) | 一种制备4-(4-氨基-3-氟苯氧基)-n-甲基吡啶-2-甲酰胺的方法 | |
CN104650048A (zh) | 一种奥美沙坦酯缩合物的纯化方法 | |
KR100829894B1 (ko) | 디메크로트산 및 그의 마그네슘염의 제조방법 | |
CN110156608A (zh) | 绿卡色林中间体对氯苯乙胺的合成方法 | |
EP1321455B1 (en) | A process for the preparation of 1-(3-trifluoromethylphenyl)-2-(2-benzoyloxyethylamino)-propane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220217 Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang hi tech park, Zhangjiang hi tech park, Pudong New Area, Shanghai Patentee after: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Patentee after: Shanghai xinlitai Pharmaceutical Co.,Ltd. Address before: Room A679-04, Building No. 2, 351 GuoShoujing Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai, 201203 Patentee before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Patentee after: Shanghai xinlitai Pharmaceutical Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Patentee before: Shanghai xinlitai Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230512 Address after: 201306 floor 3 and 4, Building 29, No. 356, ZHENGBO Road, Lingang xinpian District, China (Shanghai) pilot Free Trade Zone, Fengxian District, Shanghai Patentee after: Shanghai xinlitai Pharmaceutical Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang hi tech park, Zhangjiang hi tech park, Pudong New Area, Shanghai Patentee before: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Patentee before: Shanghai xinlitai Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right |